EGFR and non-small cell lung carcinoma: Amivantamab monotherapy was evaluated in a cohort of EGFR exon 20 insertion mutant NSCLC patients who had progressed on platinum-based chemotherapy and included an efficacy population (81 patients) and a safety population (114 patients).